Business Wire

CA-INDEX-VENTURES

10.7.2024 06:31:34 CEST | Business Wire | Press release

Share
Index Ventures Announces $2.3bn in New Funds at a Historical Inflection Point for Startups

Index Ventures, a leading global venture capital firm, today announced $2.3 billion in new funds to forge relationships with exceptional entrepreneurs who are creating transformative, category-defining businesses. Combined with Index’s existing $300 million Origin seed fund, Index is deploying $2.6 billion in capital to back founders from seed to IPO. This brings Index’s total capital raised since its founding to $15 billion.

The firm’s fundraise comes at a pivotal moment for the global startup ecosystem. The rise of transformative technologies such as AI, the emergence of tried-and-tested playbooks for hyper-growth companies, and the critical mass of experienced global talent are feeding into and accelerating one another. The result is that entrepreneurs stand at a historical tipping point in which they have unprecedented opportunities to create new, category-defining businesses.

AI opens up entirely new industries for VC investment

“Even though technology has transformed our daily lives, the reality is that it has so much further to go,” said Shardul Shah, partner at Index Ventures. “AI alone will revolutionize virtually every sector of the economy and open up whole industries to venture that have remained virtually untouched. Meanwhile, hundreds of thousands of people have worked in hypergrowth startups globally and can transfer those lessons to the next generation of companies. We’re energized by the unique opportunities that this historical moment presents and excited to partner with founders to solve the world’s trickiest and most consequential problems.”

One global team: from SF to NY, London to Tel Aviv

With its new $800 million venture fund and $1.5 billion growth fund, Index is positioned to be the best long-term partner for entrepreneurs building upon this new foundation wherever they are in the world. Index has a meaningful presence from San Francisco in the West to Tel Aviv in the East – spanning ten time zones and 24 of the world’s 30 most vibrant ecosystems. Established on the West Coast with a portfolio that includes Figma, Discord, Notion, and Roblox, Index has stepped up its US presence with a new New York office. This means it can partner closely with category leaders like Datadog, as well as startups such as Wiz and DataSnipper, using New York as a bridge to help them expand from Europe and Israel across the US. Index has continued strengthening its US leadership by welcoming former Airbnb executive Vlad Loktev to the San Francisco office, who was instrumental in driving Airbnb’s growth and product strategy for over a decade at the company.

Three decades of investing: 108 unicorns, 57 IPOs, 200,000 jobs

Index has a nearly three-decade history of identifying, nurturing, and partnering with visionary founders. Most of these partnerships begin early in a company’s life, at Seed and Series A. Index has invested in 109 companies that reached a $1 billion valuation, 23 that exceeded a $10 billion valuation, and 57 that became publicly traded. The businesses in the Index portfolio have created 200,000 jobs so far and are on track to hire 20,000 more in the next 12 months. Recent highlights from the Index portfolio include:

  • Wiz, the cloud security company in which Index was an early investor, grew to 100x its value within 18 months – becoming the fastest-ever company to hit $100m ARR in that time. Wiz has now reached over $350m in ARR and serves over 40% of the Fortune 100;
  • Scale AI recently raised $1bn and doubled its valuation to $14 billion, and its data foundry powers nearly every leading large language model;
  • DeepL, the language AI company, is transforming the language industry, which is projected to grow to $95.3 billion by 2028. Index led DeepL’s $300M raise at a $2 billion valuation earlier this year;
  • Revolut, the all-in-one finance platform, announced revenues exceeding $2.2 billion for 2023, with record pre-tax profits of $545 million and 45 million customers globally

When Index’s founders succeed, they generate outsized returns for the firm’s limited partners, which include non-profit foundations, educational endowments, healthcare and research institutions, and other impact-oriented organizations.

About Index Ventures

Index Ventures is a global venture capital firm that backs exceptional entrepreneurs. We help founders turn their bold ideas into global businesses and, through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale-up journey, we forge deep and long-lasting relationships with founders and their teams across many industries and geographies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709136755/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye